Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target

• Published in: Journal of controlled release Vol. 220; no. Pt B; pp. 758 - 765
• Main Authors: Waters, Nigel J., Daigle, Scott R., Rehlaender, Bruce N., Basavapathruni, Aravind, Campbell, Carly T., Jensen, Tyler B., Truitt, Brett F., Olhava, Edward J., Pollock, Roy M., Stickland, Kim A., Dovletoglou, Angelos
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 28.12.2015
• Subjects: Administration, Oral; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - blood; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacokinetics; Benzimidazoles - administration & dosage; Benzimidazoles - blood; Benzimidazoles - chemistry; Benzimidazoles - pharmacokinetics; Biological Availability; Chemistry, Pharmaceutical; Continuous IV; Delayed-Action Preparations; DNA Methylation - drug effects; Dogs; DOT1L; Drug Administration Schedule; Drug Carriers; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - blood; Enzyme Inhibitors - chemistry; Enzyme Inhibitors - pharmacokinetics; Epigenesis, Genetic - drug effects; EPZ-5676; Gene Expression Regulation, Leukemic - drug effects; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Biphenotypic, Acute - drug therapy; Leukemia, Biphenotypic, Acute - enzymology; Leukemia, Biphenotypic, Acute - genetics; Leukemia, Biphenotypic, Acute - pathology; Male; Methyltransferases - antagonists & inhibitors; Methyltransferases - metabolism; Mice; MLL-r; Pinometostat; Rats, Sprague-Dawley; Subcutaneous; Tumor Burden - drug effects; Xenograft Model Antitumor Assays; MLL-r; EPZ-5676; Pinometostat; Subcutaneous; Pinometostat (EPZ-5676); Continuous IV; DOT1L
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2015.09.023

Protein methyltransferases are emerging as promising drug targets for therapeutic intervention in human cancers. Pinometostat (EPZ-5676) is a small molecule inhibitor of the DOT1L enzyme, a histone methyltransferase that methylates lysine 79 of histone H3. DOT1L activity is dysregulated in the pathophysiology of rearranged mixed lineage leukemia (MLL-r). Pinometostat is currently in Phase 1 clinical trials in relapsed refractory acute leukemia patients and is administered as a continuous IV infusion (CIV). The studies herein investigated alternatives to CIV administration of pinometostat to improve patient convenience. Various sustained release technologies were considered, and based on the required dose size as well as practical considerations, subcutaneous (SC) bolus administration of a solution formulation was selected for further evaluation in preclinical studies. SC administration offered improved exposure and complete bioavailability of pinometostat relative to CIV and oral administration. These findings warranted further evaluation in rat xenograft models of MLL-r leukemia. SC dosing in xenograft models demonstrated inhibition of MLL-r tumor growth and inhibition of pharmacodynamic markers of DOT1L activity. However, a dosing frequency of thrice daily (t.i.d) was required in these studies to elicit optimal inhibition of DOT1L target genes and tumor growth inhibition. Development of an extended release formulation may prove useful in the further optimization of the SC delivery of pinometostat, moving towards a more convenient dosing paradigm for patients. [Display omitted]